XML 36 R22.htm IDEA: XBRL DOCUMENT
v3.19.1

Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2018
Notes Tables |
Debt Securities, Available-for-sale [Table Text Block] |
|  | December 31, 2018
|  | Amortized Cost |  | Accrued Interest |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Obligations of U.S. Government and its agencies |  | $ | 50,613 |  |  | $ | 176 |  |  | $ | 15 |  |  | $ | (131 | ) |  | $ | 50,673 |
Corporate debt securities |  |  | 45,793 |  |  |  | 254 |  |  |  | 4 |  |  |  | (171 | ) |  |  | 45,880 |
Certificates of deposit |  |  | 3,559 |  |  |  | 14 |  |  |  | - |  |  |  | (14 | ) |  |  | 3,559 |
Total investments |  | $ | 99,965 |  |  | $ | 444 |  |  | $ | 19 |  |  | $ | (316 | ) |  | $ | 100,112 |
|  | December 31, 2017
|  | Amortized Cost |  | Accrued Interest |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Obligations of U.S. Government and its agencies |  | $ | 60,121 |  |  | $ | 177 |  |  | $ | - |  |  | $ | (122 | ) |  | $ | 60,176 |
Corporate debt securities |  |  | 34,021 |  |  |  | 203 |  |  |  | - |  |  |  | (108 | ) |  |  | 34,116 |
Certificates of deposit |  |  | 11,099 |  |  |  | 32 |  |  |  | 1 |  |  |  | (14 | ) |  |  | 11,118 |
Total investments |  | $ | 105,241 |  |  | $ | 412 |  |  | $ | 1 |  |  | $ | (244 | ) |  | $ | 105,410 |
Available For Sale Securities Debt Maturities Fair Value [Table Text Block] |
|  | 2018 |  | 2017
Maturing in one year or less |  | $ | 77,736 |  |  | $ | 64,115 |
Maturing after one year through two years |  |  | 22,376 |  |  |  | 34,257 |
Maturing after two years |  |  | - |  |  |  | 7,038 |
Total investments |  | $ | 100,112 |  |  | $ | 105,410 |
Schedule of Receivables from Collaborations [Table Text Block] |
|  | December 31, 2018
|  | Billed |  | Unbilled |  | Total
U.S. Department of Health and Human Services |  | $ | - |  |  | $ | 1,525 |  |  | $ | 1,525 |
Shionogi & Co. Ltd. |  |  | 854 |  |  |  | - |  |  |  | 854 |
Green Cross Corporation |  |  | 876 |  |  |  | 28 |  |  |  | 904 |
Mundipharma International Holdings Limited |  |  | 44 |  |  |  | - |  |  |  | 44 |
Seqirus UK Limited |  |  | 940 |  |  |  | 26 |  |  |  | 966 |
Total receivables |  | $ | 2,714 |  |  | $ | 1,579 |  |  | $ | 4,293 |
|  | December 31, 2017
|  | Billed |  | Unbilled |  | Total
U.S. Department of Health and Human Services |  | $ | 42 |  |  | $ | 2,020 |  |  | $ | 2,062 |
Shionogi & Co. Ltd. |  |  | 1,600 |  |  |  | - |  |  |  | 1,600 |
Green Cross Corporation |  |  | 1,388 |  |  |  | 28 |  |  |  | 1,416 |
Mundipharma International Holdings Limited |  |  | 47 |  |  |  | - |  |  |  | 47 |
Seqirus UK Limited |  |  | 825 |  |  |  | 167 |  |  |  | 992 |
Total receivables |  | $ | 3,902 |  |  | $ | 2,215 |  |  | $ | 6,117 |
Schedule of Accrued Liabilities [Table Text Block] |
|  | December 31,
|  | 2018 |  | 2017
Compensation and benefits |  | $ | 4,659 |  |  | $ | 2,905 |
Development costs |  |  | 7,564 |  |  |  | 6,683 |
Inventory |  |  | 1,649 |  |  |  | - |
Professional fees |  |  | 118 |  |  |  | 729 |
Duties and taxes |  |  | 51 |  |  |  | 148 |
Other |  |  | 1,850 |  |  |  | 2,234 |
Total accrued expenses |  | $ | 15,891 |  |  | $ | 12,699 |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] |
|  | Balance at December 31, 2017 |  | Adjustments due to ASC 606 |  | Balance at January 1, 2018
Assets |  |  |  |  |  |  |  |  |  |  |  |
Deferred collaboration expense |  | $ | 210 |  |  | $ | (58 | ) |  | $ | 152 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 8,484 |  |  | $ | (1,184 | ) |  | $ | 7,300 |
Equity |  |  |  |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | (631,843 | ) |  | $ | 1,126 |  |  | $ | (630,717 | )
|  | December 31, 2018
|  | As Reported |  | Adjustments due to ASC 606 |  | Balances without adoption of ASC 606
Assets |  |  |  |  |  |
Deferred collaboration expense |  | $ | 9 |  |  | $ | - |  |  | $ | 9 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 221 |  |  | $ | - |  |  | $ | 221 |
Equity |  |  |  |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | (731,969 | ) |  | $ | - |  |  | $ | (731,969 | )
|  | For the Twelve Months Ended December 31, 2018
|  | As Reported |  | Adjustments due to ASC 606 |  | Balances without adoption of ASC 606
Collaborative and other research and development revenue |  | $ | 14,552 |  |  | $ | 1,184 |  |  | $ | 15,736 |
Research and development expenses |  |  | 84,888 |  |  |  | 58 |  |  |  | 84,946 |
Net loss |  |  | (101,252 | ) |  |  | 1,126 |  |  |  | (100,126 | )
Basic and diluted net loss per share |  | $ | (0.98 | ) |  | $ | 0.01 |  |  | $ | (0.97 | )
Disaggregation of Revenue [Table Text Block] |
|  | 2018 |  | 2017 |  | 2016
Product sales, net |  | $ | - |  |  | $ | 1,501 |  |  | $ | 2,269 |
Royalty revenue |  |  | 6,101 |  |  |  | 10,543 |  |  |  | 9,682 |
Collaborative and other research and development revenues: |  |  |  |  |  |  |  |  |  |  |  |
U.S. Department of Health and Human Services |  |  | 2,552 |  |  |  | 4,608 |  |  |  | 12,449 |
Shionogi & Co. Ltd. |  |  | - |  |  |  | 1,184 |  |  |  | 1,184 |
Seqirus UK Limited |  |  | 12,000 |  |  |  | 7,350 |  |  |  | 769 |
Total collaborative and other research and development revenues |  |  | 14,552 |  |  |  | 13,142 |  |  |  | 14,402 |
Total revenues |  | $ | 20,653 |  |  | $ | 25,186 |  |  | $ | 26,353 |

X
- Definition Tabular disclosure of available for sale securities debt maturities fair value. + References No definition available. + Details
Name: | bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock
Namespace Prefix: | bcrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure representing receivables from collaborations. + References No definition available. + Details
Name: | bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock
Namespace Prefix: | bcrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 + Details
Name: | us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accrued liabilities. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.10-01.(b)(6)) -URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 + Details
Name: | us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration